What's in the Cards for Amgen (AMGN) This Earnings Season?
https://www.zacks.com/stock/news/2264395/what-s-in-the-cards-for-amgen-amgn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2264395
Apr 29, 2024 - Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
0
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322
Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
0
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2226983/alnylam-alny-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2226983
Feb 15, 2024 - While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0